Overview
The marketing authorisation for Clopidogrel Acino Pharma has been withdrawn at the request of the marketing-authorisation holder.
Clopidogrel Acino Pharma : EPAR - Summary for the public
English (EN)
(490.35 KB - PDF)View
български (BG)
(422.82 KB - PDF)
español (ES)
(264.44 KB - PDF)
čeština (CS)
(396.68 KB - PDF)
dansk (DA)
(264.16 KB - PDF)
Deutsch (DE)
(265.14 KB - PDF)
eesti keel (ET)
(263.42 KB - PDF)
ελληνικά (EL)
(433.13 KB - PDF)
français (FR)
(264.52 KB - PDF)
italiano (IT)
(264.01 KB - PDF)
latviešu valoda (LV)
(394.91 KB - PDF)
lietuvių kalba (LT)
(373.48 KB - PDF)
magyar (HU)
(387.3 KB - PDF)
Malti (MT)
(397.13 KB - PDF)
Nederlands (NL)
(264.16 KB - PDF)
polski (PL)
(402.16 KB - PDF)
português (PT)
(264.19 KB - PDF)
română (RO)
(367.16 KB - PDF)
slovenčina (SK)
(392.42 KB - PDF)
slovenščina (SL)
(351.09 KB - PDF)
Suomi (FI)
(263.52 KB - PDF)
svenska (SV)
(263.84 KB - PDF)
Product information
Clopidogrel Acino Pharma : EPAR - Product Information
English (EN)
(838.86 KB - PDF)View
български (BG)
(1.01 MB - PDF)
español (ES)
(459.16 KB - PDF)
čeština (CS)
(772.42 KB - PDF)
dansk (DA)
(453.93 KB - PDF)
Deutsch (DE)
(465.62 KB - PDF)
eesti keel (ET)
(450.22 KB - PDF)
ελληνικά (EL)
(1.04 MB - PDF)
français (FR)
(464.05 KB - PDF)
íslenska (IS)
(141.37 KB - PDF)
italiano (IT)
(457.81 KB - PDF)
latviešu valoda (LV)
(829.82 KB - PDF)
lietuvių kalba (LT)
(527.97 KB - PDF)
magyar (HU)
(811.79 KB - PDF)
Malti (MT)
(787.47 KB - PDF)
Nederlands (NL)
(458.87 KB - PDF)
norsk (NO)
(135.18 KB - PDF)
polski (PL)
(823.34 KB - PDF)
português (PT)
(459.85 KB - PDF)
română (RO)
(537.98 KB - PDF)
slovenčina (SK)
(771.29 KB - PDF)
slovenščina (SL)
(744.06 KB - PDF)
Suomi (FI)
(455.44 KB - PDF)
svenska (SV)
(469.69 KB - PDF)
Latest procedure affecting product information: A20/0004
09/02/2012
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Clopidogrel Acino Pharma : EPAR - All Authorised presentations
English (EN)
(458.6 KB - PDF)View
български (BG)
(326.17 KB - PDF)
español (ES)
(226.07 KB - PDF)
čeština (CS)
(299.25 KB - PDF)
dansk (DA)
(243.5 KB - PDF)
Deutsch (DE)
(225.49 KB - PDF)
eesti keel (ET)
(225.9 KB - PDF)
ελληνικά (EL)
(323.64 KB - PDF)
français (FR)
(229.09 KB - PDF)
italiano (IT)
(225 KB - PDF)
latviešu valoda (LV)
(304.69 KB - PDF)
lietuvių kalba (LT)
(309.26 KB - PDF)
magyar (HU)
(301.61 KB - PDF)
Malti (MT)
(300.19 KB - PDF)
Nederlands (NL)
(225.42 KB - PDF)
polski (PL)
(265.93 KB - PDF)
português (PT)
(225.68 KB - PDF)
română (RO)
(290.89 KB - PDF)
slovenčina (SK)
(264.24 KB - PDF)
slovenščina (SL)
(234.82 KB - PDF)
Suomi (FI)
(228.74 KB - PDF)
svenska (SV)
(225.4 KB - PDF)
Product details
- Name of medicine
- Clopidogrel Acino Pharma
- Active substance
- clopidogrel
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Peripheral Vascular Diseases
- Stroke
- Myocardial Infarction
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
For further information please refer to section 5.1.
Assessment history
This page was last updated on